Our product line is led by our ultra-long acting, low-toxicity local anesthetic medication, Enduracaine™.

Enduracaine™ is a novel combination of three well-known, extremely safe and effective local anesthetics. The combination delivers advanced pain management performance.

Enduracaine™ produces an aqueous solution of 0.4% lidocaine with 0.2% tetracaine and 4mcg per milliliter of epinephrine.

Ventis Pharma is conducting ongoing research into user-friendly, moderate-cost adjuvants to enhance other local anesthetic applications. Given recent consensus statements from the American Society of Anesthesiologists in their publication “Anesthesiology” regarding the lack of efficacy of the liposomal encapsulated bupivacaine products, we believe there is a growing need for safe and effective local anesthetic products and adjuvants.

While there are other drugs in the FDA approval process that claim to provide an extended local anesthetic effect, they all utilize some formulation of the local anesthetic bupivacaine, which has a long history of significant cardiovascular risks. Worryingly, there are also formulations in the approval process which combine this toxic drug with a non-steroidal anti-inflammatory drug that was removed from the market due to adverse drug reaction concerns.

Enduracaine™ eliminates these risks with a safer, more effective formula.